Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1COVID-19 1

Interventions

Olanzapine 4Cyclophosphamide 4Voriconazole 3Tranexamic Acid 3Standard of Care 3nilotinib 2letermovir 2fludarabine phosphate 2Zoledronic Acid 2Whole-Body Irradiation 2Practice Guidelines as Topic 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Methods 2Imatinib Mesylate 2Educational Status 2Early Intervention, Educational 2Doxorubicin 2Cyclosporins 2Cyclosporine 2venetoclax 1trihexyltetradecylphosphonium chloride 1thymoglobulin 1shengxuening 1posaconazole 1pembrolizumab 1olaparib 1maribavir 1lenvatinib 1ferrous succinate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Hematologic Neoplasms × BNT162 Vaccine × Clear all
NCT04951323 2022-05-18

Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)

University of Liege

Phase 3 Unknown
50 enrolled
Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡